Tectonic Therapeutic (TECX) Expected to Announce Earnings on Thursday

Tectonic Therapeutic (NASDAQ:TECX) is expected to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Tectonic Therapeutic to post earnings of ($1.16) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

Tectonic Therapeutic (NASDAQ:TECX) last released its earnings results on Thursday, February 26th. The company reported ($1.03) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.08. On average, analysts expect Tectonic Therapeutic to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Tectonic Therapeutic Stock Performance

Tectonic Therapeutic stock traded down $0.28 during midday trading on Tuesday, reaching $29.37. The company’s stock had a trading volume of 70,383 shares, compared to its average volume of 325,673. The firm has a market capitalization of $553.68 million, a PE ratio of -7.22 and a beta of 3.27. The stock’s 50 day simple moving average is $29.08 and its 200 day simple moving average is $23.12. Tectonic Therapeutic has a fifty-two week low of $14.39 and a fifty-two week high of $36.03.

Analyst Ratings Changes

TECX has been the subject of a number of recent research reports. Stifel Nicolaus initiated coverage on Tectonic Therapeutic in a research report on Monday, April 13th. They set a “buy” rating and a $75.00 price objective for the company. Wall Street Zen cut Tectonic Therapeutic from a “sell” rating to a “strong sell” rating in a report on Saturday, April 18th. Truist Financial cut their price target on shares of Tectonic Therapeutic from $64.00 to $60.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Lifesci Capital raised shares of Tectonic Therapeutic to a “strong-buy” rating in a research note on Thursday, February 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tectonic Therapeutic in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $80.57.

Insider Activity

In related news, CFO Daniel Lochner bought 6,000 shares of the company’s stock in a transaction on Tuesday, February 10th. The shares were purchased at an average cost of $21.61 per share, with a total value of $129,660.00. Following the completion of the transaction, the chief financial officer directly owned 32,044 shares of the company’s stock, valued at approximately $692,470.84. This represents a 23.04% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Peter Mcnamara sold 6,262 shares of the stock in a transaction on Friday, March 6th. The stock was sold at an average price of $30.17, for a total value of $188,924.54. Following the completion of the sale, the insider directly owned 55,285 shares in the company, valued at $1,667,948.45. This represents a 10.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 20,561 shares of company stock worth $597,601. 39.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Tectonic Therapeutic

Several large investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd increased its holdings in shares of Tectonic Therapeutic by 451.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 3,966 shares of the company’s stock valued at $62,000 after purchasing an additional 3,247 shares during the period. New York State Common Retirement Fund acquired a new position in shares of Tectonic Therapeutic during the second quarter valued at $99,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Tectonic Therapeutic during the second quarter valued at $119,000. JPMorgan Chase & Co. increased its holdings in shares of Tectonic Therapeutic by 483.6% during the second quarter. JPMorgan Chase & Co. now owns 6,548 shares of the company’s stock valued at $130,000 after purchasing an additional 5,426 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Tectonic Therapeutic during the fourth quarter valued at $134,000. 62.63% of the stock is owned by institutional investors and hedge funds.

About Tectonic Therapeutic

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.